曼月乐辅以亮丙瑞林对子宫腺肌症的疗效及痛经VAS评分的影响

Effect of mirena combined with leuprorelin on adenomyosis and VAS score of dysmenorrhea

目的探讨曼月乐辅以亮丙瑞林对子宫腺肌症的疗效及痛经VAS评分的影响。方法选取2017年10月~2019年10月在院确诊为子宫腺肌症患者80例,随机数字表法均分为对照组和研究组,各40例,对照组予以亮丙瑞林,研究组在对照组的基础上予以曼月乐,比较两组疗效以及治疗前后VAS评分。结果研究组治疗后月经量(41.8±9.2)ml、子宫体积(101.6±27.5)cm3、子宫内膜厚度(3.6±0.5)mm,均显著低于对照组,研究组不良反应发生率2.50%显著低于对照组,且研究组治疗后1个月、3个月、6个月的VAS评分(1.11±0.10)分、(0.63±0.25)分、(0.68±0.22)分均显著低于对照组(P<0.05)。结论曼月乐联合亮丙瑞林使用比单纯应用亮丙瑞林对于子宫腺肌症患者具有更好的疗效,安全性高。

Objective To investigate the effect of mirena combined with leuprorelin on adenomyosis and VAS score of dysmenorrhea.Methods From October 2017 to October 2019,80 patients diagnosed with adenomyosis in our hospital were selected as objects,and the random number table method was used to divide the patients into the control group and the research group,with 40 cases in each group.The control group was given leuprorelin,and the research group was given mirena on the basis of the control group,and the efficacy of the two groups and Visual Analogue Score before and after treatment were compared.Results After the treatment,The menstrual quantity of the research group was(41.8±9.2)ml,uterine volume(101.6±27.5)cm3,endometrial thickness(3.6±0.5)mm,which were significantly lower than those of the control group.The incidence of adverse reactions was 2.50%,which was significantly lower than that of the control group.And 1 month,3 months,6 months after treatment the VAS score of research group were(1.11±0.10)、(0.63±0.25)、(0.68±0.22),significantly lower than those of the control group(P<0.05).Conclusion Mirena combined with leuprorelin has better curative effect and higher safety on adenomyosis patients than leuprorelin alone,which is worthy of popularization and application.